Clinically relevant aminoglycosides can suppress disease-associated premature stop mutations in the IDUA and P53 cDNAs in a mammalian translation system.
about
Reawakening retrocyclins: ancestral human defensins active against HIV-1The effect of eukaryotic release factor depletion on translation termination in human cell linesNew approaches to the treatment of orphan genetic disorders: Mitigating molecular pathologies using chemicalsTherapeutic suppression of premature termination codons: mechanisms and clinical considerations (review)Aminoglycosides restore full-length type VII collagen by overcoming premature termination codons: therapeutic implications for dystrophic epidermolysis bullosa.Molecular dissection of translation termination mechanism identifies two new critical regions in eRF1.Aminoglycosides, but not PTC124 (Ataluren), rescue nonsense mutations in the leptin receptor and in luciferase reporter genes.New trends in aminoglycosides use.Cystic fibrosis transmembrane conductance regulator protein repair as a therapeutic strategy in cystic fibrosisTranslational read-through as an alternative approach for ocular gene therapy of retinal dystrophies caused by in-frame nonsense mutations.Statistical analysis of readthrough levels for nonsense mutations in mammalian cells reveals a major determinant of response to gentamicin.5-azacytidine inhibits nonsense-mediated decay in a MYC-dependent fashion.Ataluren stimulates ribosomal selection of near-cognate tRNAs to promote nonsense suppression.Nonsense-mediated decay in genetic disease: friend or foe?PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR-G542X nonsense allele in a CF mouse modelSuppression of nonsense mutations as a therapeutic approach to treat genetic diseases.Emerging drug treatments for cystic fibrosis.The designer aminoglycoside NB84 significantly reduces glycosaminoglycan accumulation associated with MPS I-H in the Idua-W392X mouse.No detectable improvements in cystic fibrosis transmembrane conductance regulator by nasal aminoglycosides in patients with cystic fibrosis with stop mutations.Production of beta-globin and adult hemoglobin following G418 treatment of erythroid precursor cells from homozygous beta(0)39 thalassemia patients.G418-mediated ribosomal read-through of a nonsense mutation causing autosomal recessive proximal renal tubular acidosis.Cytoplasmic and intra-nuclear binding of gentamicin does not require endocytosis.Stably integrated luxCDABE for assessment of Salmonella invasion kinetics.Characterization of an MPS I-H knock-in mouse that carries a nonsense mutation analogous to the human IDUA-W402X mutation.Correction of ATM gene function by aminoglycoside-induced read-through of premature termination codons.Ataluren as an agent for therapeutic nonsense suppression.Nonsense Suppression as an Approach to Treat Lysosomal Storage Diseases.Mesh biocompatibility: effects of cellular inflammation and tissue remodelling.Canine ocular tumors following ciliary body ablation with intravitreal gentamicin.Readthrough strategies for therapeutic suppression of nonsense mutations in inherited metabolic disease.Use of RNA in drug design.Therapeutic targets associated to E-cadherin dysfunction in gastric cancer.Novel therapeutic approaches for haemophilia.Antibiotics inhibit sphere-forming ability in suspension cultureTargeting Nonsense Mutations in Diseases with Translational Read-Through-Inducing Drugs (TRIDs).Alternative splicing of in-frame exon associated with premature termination codons: implications for readthrough therapies.Control of gene expression through the nonsense-mediated RNA decay pathway.Characterization of the melanocortin-4-receptor nonsense mutation W16X in vitro and in vivo.Differential functional readthrough over homozygous nonsense mutations contributes to the bleeding phenotype in coagulation factor VII deficiency.Rescue of non-sense mutated p53 tumor suppressor gene by aminoglycosides.
P2860
Q21145822-56C7EDE0-7F31-438E-B158-D9A5FC39287AQ24301805-C08B46C8-8690-451C-A063-4CB900530137Q26801582-70145EE2-64F4-4B1A-974D-F74AB6253308Q26853614-0ED4A84F-0523-4BB1-8EEA-545018BF4316Q30650123-3DA77936-D57A-482F-9431-F76883DCCC97Q33403468-2806FBC1-E104-48A2-9F5D-53EF2F3B6336Q33681878-19F240F1-F8E1-42D0-A264-4BF429AA90C0Q33951177-1CDB0926-CE2B-4618-AE15-F5DF8A46B102Q34023921-D67DDDAF-EF02-48C4-8E60-99E0901EB43BQ34041207-24265224-EB5A-49CF-B91B-1818DF22F7C4Q34221047-55EE5614-683B-4358-9A2C-BC29F9A2DF0AQ34443734-035461BD-596A-471E-9C44-4E980D082527Q34541951-50E8D859-F91F-4036-9863-F97E489110CCQ34658988-80E7777E-9168-47EA-99FD-B574AC8B8A34Q34749864-7C6BF1B3-C062-4E8C-8170-2DC6F0F3DD59Q35287888-1A381AD8-A86B-4C1C-B433-7B240C5B1763Q35602683-075BAA23-B146-40E4-B7CB-F8003584248BQ35661233-9F2E7216-F491-42C1-804A-AFD9DC03630FQ35855342-DFBD10FC-7C74-4005-BC69-21D40F7B8AF0Q36611332-ECAD37AE-CCBD-46EF-97BF-0338C963ACCEQ37121624-4C9F39F4-0A8D-40C1-855E-E5BC2A0A68D0Q37328789-970A8F3A-58AE-4735-9BE2-55D6167AC66BQ37345435-B448BC31-059E-43FF-BC44-68168C45D863Q37480537-6C710323-7635-42DA-BCB2-344DD5BC64EAQ37595569-5C730112-86D3-4DDF-9425-C0771048748AQ37670599-A521968C-7259-4E64-B074-113AB99E3A09Q37726532-767E11BB-8BD0-4FFA-A361-A14F7C785698Q37860197-6B457AB1-8135-4593-BAF1-BBE3BE14E16FQ38027555-E9226BE5-984F-45D1-AD4B-089909886E47Q38072030-CEA36210-7E75-4284-B194-22E7941C705FQ38089160-246777CF-0B12-46EE-8D10-858897CAF356Q38129925-95EC045F-5A63-4610-BEB7-9FC08391B404Q38293116-32A48A76-4207-411B-BA8D-42EC4A26D41BQ38383686-86EB256F-F1EA-4135-B098-5349DAE98467Q38737126-6F02FDE2-7CF5-490D-820E-DF81F4E43326Q39259322-8BBAF073-B434-4761-AF02-670963F98987Q39323825-C2A9FD81-82DF-47CF-89F8-85FB03C5A1D0Q39463665-738475C6-A219-4BC3-A868-0F4D27E77B51Q39499656-643920DE-4530-4A77-B4B4-772D0AF6D9C2Q39621228-86A5D470-FCC6-4179-8F75-E356968F1B48
P2860
Clinically relevant aminoglycosides can suppress disease-associated premature stop mutations in the IDUA and P53 cDNAs in a mammalian translation system.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh
2002年學術文章
@zh-hant
name
Clinically relevant aminoglyco ...... mammalian translation system.
@en
Clinically relevant aminoglyco ...... mammalian translation system.
@nl
type
label
Clinically relevant aminoglyco ...... mammalian translation system.
@en
Clinically relevant aminoglyco ...... mammalian translation system.
@nl
prefLabel
Clinically relevant aminoglyco ...... mammalian translation system.
@en
Clinically relevant aminoglyco ...... mammalian translation system.
@nl
P1476
Clinically relevant aminoglyco ...... mammalian translation system.
@en
P2093
David M Bedwell
Kim M Keeling
P2888
P304
P356
10.1007/S00109-001-0317-Z
P577
2002-01-25T00:00:00Z